Skip to Main Content

Clinical reality strikes three biotech companies Tuesday, dampening their stock prices:

1. Hopes have dimmed that Amicus Therapeutics (FOLD) will be able to seek marketing approval for its Pompe disease drug in 2018. A cautious regulatory update issued Tuesday caused Amicus’ stock to fall 7 percent.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!